Shanghai - Delayed Quote CNY

Jointown Pharmaceutical Group Co., Ltd (600998.SS)

Compare
4.9600
-0.0100
(-0.20%)
At close: January 3 at 3:00:01 PM GMT+8
Loading Chart for 600998.SS
DELL
  • Previous Close 4.9700
  • Open 5.0000
  • Bid 4.9600 x --
  • Ask 4.9700 x --
  • Day's Range 4.9300 - 5.0500
  • 52 Week Range 4.3500 - 8.9500
  • Volume 24,387,076
  • Avg. Volume 37,476,283
  • Market Cap (intraday) 25.011B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) 12.10
  • EPS (TTM) 0.4100
  • Earnings Date --
  • Forward Dividend & Yield 0.25 (5.04%)
  • Ex-Dividend Date Jun 7, 2024
  • 1y Target Est --

Jointown Pharmaceutical Group Co., Ltd provides pharmaceutical supply chain services in China. It is also involved in general agency brand promotion; digital retail; intelligent logistics and supply chain solutions; and medical health and technology value-added service businesses. In addition, the company manufactures western medicines, such as antibiotics, anti-diabetic drugs, and cardiovascular drugs; and other OEM medicines. The company was founded in 1999 and is based in Wuhan, China.

www.jztey.com

30,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600998.SS

View More

Performance Overview: 600998.SS

Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

600998.SS
5.16%
SSE Composite Index
5.75%

1-Year Return

600998.SS
27.45%
SSE Composite Index
8.41%

3-Year Return

600998.SS
22.02%
SSE Composite Index
11.77%

5-Year Return

600998.SS
15.89%
SSE Composite Index
4.09%

Compare To: 600998.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600998.SS

View More

Valuation Measures

As of 1/3/2025
  • Market Cap

    25.01B

  • Enterprise Value

    24.92B

  • Trailing P/E

    12.21

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.17

  • Price/Book (mrq)

    1.01

  • Enterprise Value/Revenue

    0.17

  • Enterprise Value/EBITDA

    5.98

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.37%

  • Return on Assets (ttm)

    2.67%

  • Return on Equity (ttm)

    7.15%

  • Revenue (ttm)

    149.2B

  • Net Income Avi to Common (ttm)

    2.05B

  • Diluted EPS (ttm)

    0.4100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.24B

  • Total Debt/Equity (mrq)

    43.63%

  • Levered Free Cash Flow (ttm)

    1.87B

Research Analysis: 600998.SS

View More

People Also Watch